Road to remission: A comprehensive review of therapy in uveitis

Expert Opinion on Investigational Drugs

Volumn 20, Issue 11, 2011, Pages 1497-1515

  Siddique, Sana S ^a,b   Shah, Rajiv ^a,b   Suelves, Ana M ^a,b   Foster, Charles Stephen ^a  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

Corticosteroids; Immunosuppressive therapy; Implants; Uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CERTOLIZUMAB PEGOL; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; DIFLUPREDNATE; ETANERCEPT; FLUOCINOLONE ACETONIDE; GOLIMUMAB; ILUVEIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MEDIDUR FA; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOCLOSPORIN;

CORTICOSTEROID THERAPY; EYE INFLAMMATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; REMISSION; REVIEW; STEROID THERAPY; TOPICAL TREATMENT; UVEITIS;

ADRENAL CORTEX HORMONES; ANIMALS; CLINICAL TRIALS AS TOPIC; EYE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; UVEITIS;

EID: 80053946227     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.617741     Document Type: Review

References (123)

1. Vadot E. Epidemiology of intermediate uveitis: a prospective Study in Savoy. Dev Ophthalmol 1992;23:33-4.
2. Foster CS, Vitale A. Corticosteroids. In Foster CS, Vitale A. (Ed.) Diagnosis and Treatment of Uveitis (Chapter 9; pgs 142-157).1st edition; WB Saunders Co, 2002.
3. Ng CS, Rosenthal AR. Principles of clinical management of uveitis. In: Easty DL, Sparrow JM. editors. Oxford Textbook of Ophthalmology. Oxford University Press, Inc; New York, NY: 1999. p. 553-9.
4. Bikowski J. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol 2006;5(11):125-30.
5. Gysler A, Lange K, Korting HC, Schafer-Korting M. Prednicarbate biotranformation in human foreskin keratinocytes and fibroblasts. Pharm Res 1997;14(6):793-7. (Pubitemid 27281676)
6. Foster CS, Davanzo R, Flynn TE, et al. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther 2010;26(5):475-83.
7. Korenfeld MS, Silverstein SM, Cooke DL, et al. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg 2009;35(1):26-34.
8. Smith S, Lorenz D, Peace J, et al. Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery. Clin Ophthalmol 2010;4:983-91.
9. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders progress to date. Drugs Aging 2010;27(2):117-34.
10. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-75.
11. Driot J, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-75. (Pubitemid 38849806)
12. Mruthyunjaya P, Khalatbari D, Yang P, et al. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol 2006;124:1012-18. (Pubitemid 44036324)
13. Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000;107:2024-33.
14. Package insert. Retisert (fluocinolone acetonide). Bausch & Lomb; Rochester, NY: 2005
15. Haupert CL, Jaffe GJ. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin 2000;40:205-20. (Pubitemid 30235950)
16. Retisert (fluocinolone acetonide intravitreal implant) formulary kit. Bausch & Lomb; Rochester, NY: 2005
17. Jaffe GJ, Martin DM, Callahan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-7. (Pubitemid 43795240)
18. Mahajan VB, Gehrs KM, Goldstein DA, et al. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology 2009;116(3):552-557.e1.
19. Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina 2008;28(9):1280-8.
20. Khalifa Y, Loh A, Acharya N. Fluocinolone acetonide intravitreal implants in vogt-koyanagi-harada disease. Ocul Immunol Inflamm 2009;17(6):431-3.
21. Rush RB, Goldstein DA, Callanan DG, et al. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. Am J Ophthalmol 2011. [Epub ahead of print].
22. Kempen J, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010;149(4):550-61.
23. Kupperman BD, Blumenkranz MS, Haller JA, et al; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17. (Pubitemid 46425557)
24. Williams GA, Haller JA, Kupperman BD, et al; Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147:1048-54.
25. Haller JA, Kupperman BD, Blumenkranz MS, et al; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96.
26. Lowder C, Belfort R Jr, Lightman S, et al; for the Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011 May;129(5):545-53.
27. Ghosn CR, Li Y, Orilla WC, et al. Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011. [Epub ahead of print].
28. Alimera Sciences press release. Available from: http://www. alimerasciences.com/news-pressrel-03-24-08.asp [Accessed 23 June 2008].
29. Alimera Sciences press release. Available from: http://investor. alimerasciences.com/releasedetail.cfm? ReleaseID=547652 [Accessed 3 February 2011].
30. Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 2001;9(1):35-40. (Pubitemid 32234164)
31. Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108(6):1134-9. (Pubitemid 32500033)
32. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58(1):73-81.
33. Holz FG, Krastel H, Breitbart A, et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992;1:142-4.
34. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99:1419-23.
35. Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 2003;11:131-9. (Pubitemid 37088585)
36. Gangaputra S, Newcomb CW, Liesegang TL, et al; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116(11):2188-98.e1.
37. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480.
38. Lee F, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother 2010;11(7):1135-46.
39. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989;32(7):837-43. (Pubitemid 19181005)
40. Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 1967;87:499-511.
41. Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978;96(2):247-51. (Pubitemid 8297325)
42. Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009;148:500-9.e502.
43. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13(5):335-51. (Pubitemid 41702757)
44. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149(3):423-32.e1-2.
45. Siepmann K, Huber M, Stubiger N, et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006;244:788-94. (Pubitemid 44103323)
46. Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117(3):576-84.
47. Palestine AG, Nussenblatt RB, Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transplant Proc 1988;20(3 Suppl 4):131-5.
48. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991;112(2):138-46.
49. Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010;117:356-65.
50. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121(4):437-40. (Pubitemid 36427629)
51. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 2001;9(4):219-29. (Pubitemid 34286623)
52. Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(Suppl 2):ii51-3. (Pubitemid 35221714)
53. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7(3):251-9.
54. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 2002;61(6):560-1. (Pubitemid 34539106)
55. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002;41(11):1280-5. (Pubitemid 35363803)
56. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs Tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123:634-41. (Pubitemid 40695511)
57. Hogan A, McAvoy C, Dick A, Lee R. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114(5):1000-6.
58. Cunningham M, Austin B, Li Z, et al. LX211 (Voclosporin) suppresses experimental uveitis and inhibits human T cells. Invest Ophthalmol Vis Sci 2009;50(1):249-55.
59. Anglade E, Aspeslet L, Wiess S. A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. Clin Ophthalmol 2008;2(4):693-702.
60. Augustine J, Bodziak K, Hricik D. Use of sirolimus in solid organ transplantation. Drugs 2007;67(3):369-91. (Pubitemid 46425551)
61. Lux BioSciences. Available from: http://www.luxbio.com/pr050409.htm.
62. Durmount FJ, Staruch MJ, Kprak SL, et al. Distinct mechanisms of suppression of Murine T-Cell activation by macrolides FK506 and rapamycin. J Immunol 1990;49:486-90.
63. Shanmuganathan VA, Casely E, Raj D, et al. The efficacy of sirolimus in the treatment of of patients with refractory uveitis. Br J Ophthalmol 2005;89:666-9. (Pubitemid 40780569)
64. Nussenblatt R, Coleman H, et al. The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (Rapamycin). Acta Ophthalmol Scand 2007;85(2):230-1.
65. Dugel P. Sirolimus in the treatment of Retinal Diseases. mTOR inhibitors: a new class of therapeutics. Retin Today 2009;4:38-41.
66. Nussenblatt R, Byrnes G, Sen N. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with chroidal neovascularization. Retina 2010;30(10):1579-87.
67. Reynolds J, Shojania K, Marra CA. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. Pharmacotherapy 2007;27(12):1693-701. (Pubitemid 350234316)
68. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a co-stimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-80. (Pubitemid 19138020)
69. [No authors listed] Abatacept (Orencia) for rheumatoid arthritis. Med Lett Drugs Ther 2006;48(1229):17-18.
70. Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011;249:297-300.
71. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 2010;62(6):821-5.
72. Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis-a case report. J Rheumatol 2008;35(9):1897-8.
73. Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev Immunol 1998;17:217.
74. Galor A, Perez V, Hammel J, Lowder C. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23. (Pubitemid 44838928)
75. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005;44(8):1008-11. (Pubitemid 41487173)
76. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127(6):819-22.
77. Giganti M, Beer PM, Falk N, et al. Adverse events after intravitreal infliximab (Remicade). Retina 2010;30(1):71-80.
78. Sobrin L, Kim E C, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125(7):895-900. (Pubitemid 47076425)
79. Murphy C, Ayliffe W, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6. (Pubitemid 38183244)
80. Suhler E, Smith J, Wertheim M, et al. A prospective trial of infliximab therapy for refractory uveitis. Arch Ophthalmol 2005;123:903-12.
81. Rajaraman R, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006;113:308-14. (Pubitemid 43170781)
82. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91(10):1341-4. (Pubitemid 47492870)
83. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011 Aug;41(1):61-70.
84. Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010;117(8):1612-16.
85. Campas-Moya C. Golimumab: a novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Drugs Today (Barc) 2010;46(1):13-22.
86. Smith LS, Nelson M, Dolder CR. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease. Ann Pharmacother 2010;44(2):333-42.
87. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab for non-infectious uveitis: a multicenter non-comparative interventional case series. Ophthalmology 2005;112(5):764-70. (Pubitemid 40631493)
88. Bhat P, Castaneda-Cervantes RA, Doctor PP, et al. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 2009;247(5):687-92.
89. Kiss S, Ahmed M, Letko E, et al. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 2005;112(6):1066-71. (Pubitemid 40797463)
90. Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008;126(2):186-91. (Pubitemid 351240847)
91. Finckh A, Ciurea A, Brulhart L, et al. Swiss clinical quality management programme for rheumatoid arthritis. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
92. Stone J, Merkel P, Spiera R, et al. Rituximab versus Cytoxan for ANCA associated Vasculitis. NEJM 2010;363:221-32.
93. Foster C S, Chang P, Ahmed R. Combination rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010;117(5):861-9.
94. Davatchi F, Shams H, Rezaaipoor M, et al. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13:246-52.
95. Kurz PA, Suhler EB, Choi D, et al. Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol 2009;93:546-8.
96. Kazatchkine M, Kaveri S. Immunomodulation of autoimmune and inflammatory diseae with intravenous immuneglobulin. N Engl J Med 2001;345(10):747-55.
97. Onal S, Foster CS, Ahmed AR. Efficacy of intravenous immunogloblin treatment in refractory uveitis. Ocul Immunol Inflamm 2006;14:367-74. (Pubitemid 44949896)
98. Seider N, Beiran I, Scharf J, et al. Intravenous immunoglobulin therapy for resistant ocular Behcets disease. Br J Ophthalmol 2001;85:1287-8. (Pubitemid 33016103)
99. Rosenbaum JT, George R, Gordon C. The Treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999;127(5):545-9. (Pubitemid 29215765)
100. Sekul E, Cupler E, Dalakas M. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62.
101. Hayden FG. Antiviral agents (Nonretroviral). In: Brunton LL, Lazo JS, Parker KL. editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edition. McGraw-Hill Professional; New York: 2005. p. 1243-72.
102. Feron EJ, Rothova A, van Hagen PM, et al. Interferon-alpha 2b for refractory ocular Behcet's disease. Lancet 1994;343(8910):1428. (Pubitemid 24167522)
103. Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004;33(5):311-19. (Pubitemid 38496040)
104. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33(5):320-35. (Pubitemid 38496041)
105. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998;134(8):1010-16. (Pubitemid 28385325)
106. Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 2009;3:559-66.
107. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91(3):335-9. (Pubitemid 46586530)
108. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144(1):55-61.
109. Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum 2010;62(9):2796-805.
110. Schafer J, Kjesbo N, Gleason P. Formulary review of 2 new biologic agents toclizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm 2010;16(6):402-16.
111. Brandao FM, Coelho P, Pinto P, Combe B. Tocilizumab-a new step in rheumatoid arthritis treatment. Acta Reumatol Port 2010;35(3):302-12.
112. Patel A, Moreland L. Interlukin-6 inhibition for treatment of Rheumatoid arthritis: a review of Tocilizumab therapy. Drug Design Dev Ther 2010;4:263-78.
113. Gabay C, Lamacchia C, Palmer G. IL-1 Pathways in inflammation and human diseases. Nat Rev Rheumatol 2010;6:232-41.
114. Goldbach-Mansky R. Blocking Interluckin-1 in rheumatic diseases: it's initial disappointments and recent successes in the treatment of autoinflammatory diseases. Ann NY Acad Sci 2009;1182:111-23.
115. Imrie F, Dick A. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6. (Pubitemid 351339402)
116. Nigrovic PA, Mannion M, Prince FH. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63(2):545-55.
117. Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology 2003;42(12):1539-44. (Pubitemid 37508929)
118. Foster CS. Immunosuppressive therapy for ocular inflammatory disease. Ophthalmology 1980;87:140-9.
119. Buckley CE, Durham NC, Gills JP. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med 1969;124:29-35.
120. Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978;96:247-51. (Pubitemid 8297325)
121. Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 1967;87:499-511.
122. Cervantes-Castaneda R, Bhat P, Fortuna E, et al. Induction of durable remission in ocular inflammatory diseases. Eur J Ophthalmol 2009;19(1):118-23.
123. American Academy of Ophthalmology 2010. Uveitis Subspeciality Day.